Physician profile
Melvin E Glover
NPI 1356404099
$6,100.99
in general payments reported to CMS, 2019-2025
38 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,361 · 2020: $292 · 2021: $23.17 · 2022: $1,209 · 2023: $1,118 · 2024: $1,087 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,215.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $904.44 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $877.20 | 2022-2025 | |
| Lilly USA, LLC | $768.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $559.00 | 2019-2025 | |
| Novo Nordisk INC | $549.33 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $280.11 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $253.25 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $185.79 | 2022-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $183.79 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $140.91 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Novartis Pharmaceuticals Corporation | $117.04 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.06 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $95.73 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $92.84 | 2022 | |
| Amarin Pharma, INC. | $92.18 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melvin Glover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.